This site is intended for healthcare professionals outside the US


Print |

Sandostatin® LAR® (octreotide) is a somatostatin analog. As such, its effects in the body are similar to those of the naturally occurring hormone, except that Sandostatin® LAR® remains active much longer than somatostatin.1

Octreotide suppresses secretion of growth hormone (GH), and in many cases suppresses insulin-like growth hormone-1 (IGF-1) (somatomedin C).1

Sandostatin® LAR® works centrally at the site of the tumor and binds to somatostatin receptors to regulate GH secretion and cell growth.2

  • 96% of GH-secreting pituitary tumors express the somatostatin receptor subtype, sst23

1. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2018. 2. Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol. 2003;3(6):672-677. 3. Hofland LJ, Lamberts WJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28-47.

Please see the Summary of Product Characteristics.